These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8422740)

  • 1. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
    Ujhelyi MR; O'Rangers EA; Fan C; Kluger J; Pharand C; Chow MS
    Clin Pharmacol Ther; 1993 Jan; 53(1):38-48. PubMed ID: 8422740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE; Roden DM
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolism of propafenone and lidocaine in combination in rat liver supernatant].
    Tang YN; Zhang WL; Liu L; Wang ZY
    Zhongguo Yao Li Xue Bao; 1994 Nov; 15(6):536-9. PubMed ID: 7709755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
    Pritchett EL; Smith WM; Kirsten EB
    J Clin Pharmacol; 1988 Jul; 28(7):619-24. PubMed ID: 3063727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
    Anzenbacherová E; Anzenbacher P; Perlik F; Kvetina J
    Int J Clin Pharmacol Ther; 2000 Sep; 38(9):426-9. PubMed ID: 11020029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G; Gong PL; Qiu J; Zeng FD; Klotz U
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
    Cai WM; Zhang YD; Chen B; Cai MH; Luo JP; Ling SS
    Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propafenone: a new antiarrhythmic agent.
    Chow MS; Lebsack C; Hilleman D
    Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK; Fischer C; Meese CO; Eichelbaum M
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between digoxin and propafenone.
    Calvo MV; Martin-Suarez A; Martin Luengo C; Avila C; Cascon M; Domínguez-Gil Hurlé A
    Ther Drug Monit; 1989; 11(1):10-5. PubMed ID: 2911842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin.
    Inglis AM; Sheth SB; Hursting MJ; Tenero DM; Graham AM; DiCicco RA
    Am J Health Syst Pharm; 2002 Jul; 59(13):1258-66. PubMed ID: 12116891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.